文献速递药物相互作用

生理药代动力学模型支持比克替拉韦药物相互作用临床管理

Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
PubMed 文献 · Clin Pharmacol Ther · 2021-03-29

比克替拉韦经CYP3A和UGT1A1同等代谢,仅与强抑制剂/诱导剂做过DDI研究。本研究用PBPK模型模拟多种DDI场景,预测值与临床观察数据AUC比值均在1.25倍内,提示比克替拉韦可与中度双重肇事药(如依非韦伦)合用,但不应与强CYP3A/UGT1A1抑制剂和诱导剂合用。

要点

  • 比克替拉韦不应与强CYP3A和UGT1A1抑制剂或诱导剂(如阿扎那韦、尼洛替尼、利福平)合用。
  • 基于模型结果,比克替拉韦可与中度双重肇事药(如依非韦伦)合用。
  • 利福平的诱导效应可被强抑制剂(如利托那韦)逆转,DDI幅度在0.5-2.4倍疗效安全窗内。

核心结论

  • PBPK建模策略可有效指导临床经验有限的新药(如比克替拉韦)的DDI临床管理。

研究设计与样本

  • 采用生理药代动力学(PBPK)建模模拟比克替拉韦多种DDI场景,并与临床观察DDI数据进行验证。

主要发现

  • 比克替拉韦与伏立康唑、达芦那韦/考比司他、阿扎那韦/考比司他、利福平合用的临床观察DDI数据落在PBPK模型模拟的95%置信区间内。
  • DDI与对照场景的AUC比值预测值始终在临床观察数据1.25倍以内,证明所用建模方法具有预测能力。
  • 模拟结果提示比克替拉韦不应与强CYP3A和UGT1A1抑制剂及诱导剂(如阿扎那韦、尼洛替尼、利福平)合用。
  • 基于当前建模结果,比克替拉韦可与中度双重肇事药(如依非韦伦)合用。
  • 利福平对比克替拉韦的诱导效应在与强抑制剂(如利托那韦)合用时被预测可逆转,DDI幅度在比克替拉韦疗效和安全性范围(0.5-2.4倍)内。

关键数值与推荐

  • DDI与对照场景的AUC比值预测值在临床观察数据1.25倍以内。
  • 比克替拉韦与利托那韦合用逆转利福平诱导效应后,DDI幅度在0.5-2.4倍疗效和安全性范围内。

临床怎么用

  • 临床应避免比克替拉韦与强CYP3A和UGT1A1抑制剂或诱导剂(如阿扎那韦、尼洛替尼、利福平)合用。
  • 基于PBPK模型结果,比克替拉韦可与中度双重肇事药(如依非韦伦)合用。
  • 利福平与强抑制剂(如利托那韦)合用时,可比克替拉韦的DDI幅度在疗效安全窗内,可考虑合用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bictegravir is equally metabolized by cytochrome P450 (CYP)3A and uridine diphosphate-glucuronosyltransferase (UGT)1A1. Drug-drug interaction (DDI) studies were only conducted for strong inhibitors and inducers, leading to some uncertainty whether moderate perpetrators or multiple drug associations can be safely coadministered with bictegravir. We used physiologically-based pharmacokinetic (PBPK) modeling to simulate DDI magnitudes of various scenarios to guide the clinical DDI management of bictegravir. Clinically observed DDI data for bictegravir coadministered with voriconazole, darunavir/cobicistat, atazanavir/cobicistat, and rifampicin were predicted within the 95% confidence interval of the PBPK model simulations. The area under the curve (AUC) ratio of the DDI divided by the control scenario was always predicted within 1.25-fold of the clinically observed data, demonstrating the predictive capability of the used modeling approach. After the successful verification, various DDI scenarios with drug pairs and multiple concomitant drugs were simulated to analyze their effect on bictegravir exposure. Generally, our simulation results suggest that bictegravir should not be coadministered with strong CYP3A and UGT1A1 inhibitors and inducers (e.g., atazanavir, nilotinib, and rifampicin), but based on the present modeling results, bictegravir could be administered with moderate dual perpetrators (e.g., efavirenz). Importantly, the inducing effect of rifampicin on bictegravir was predicted to be reversed with the concomitant administration of a strong inhibitor such as ritonavir, resulting in a DDI magnitude within the efficacy and safety margin for bictegravir (0.5-2.4-fold). In conclusion, the PBPK modeling strategy can effectively be used to guide the clinical management of DDIs for novel drugs with limited clinical experience, such as bictegravir.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stader F, Battegay M, Marzolini C, et al. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir. Clin Pharmacol Ther. 2021. PMID: 33626178. doi:10.1002/cpt.2221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。